Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Fulvestrant and anastrozole show benefit for improved breast cancer survival
September 1st, 2005
Fulvestrant and anastrozole show a benefit for improved breast cancer survival. "Fulvestrant is an estrogen receptor antagonist with no agonist effects," stated investigators at Christie Hospital, United Kingdom. "In the second-line treatment of advanced breast carcinoma, fulvestrant was shown previously to be as effective as the third-generation aromatase inhibitor, anastrozole, in terms of time to disease progression and objective response rates." "The authors," A. Howell and colleagues, "reported the overall survival results from these studies. A prospectively planned, combined, overall survival analysis was performed, including data from two...
Source: Women's Health Weekly (2005-09-01)
|
